Linda Arsenault - Amylyx Pharmaceuticals Chief Officer

AMLX Etf  USD 5.54  0.20  3.48%   
Linda Arsenault is Portfolio Manager at Amylyx Pharmaceuticals
Address 43 Thorndike Street, Cambridge, MA, United States, 02141
Phone617 682 0917
Webhttps://amylyx.com

Amylyx Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (0.4344) % which means that it has lost $0.4344 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.8443) %, meaning that it created substantial loss on money invested by shareholders. Amylyx Pharmaceuticals' management efficiency ratios could be used to measure how well Amylyx Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Amylyx Pharmaceuticals currently holds 4.24 M in liabilities with Debt to Equity (D/E) ratio of 0.04, which may suggest the company is not taking enough advantage from borrowing. Amylyx Pharmaceuticals has a current ratio of 7.8, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Amylyx Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Amylyx Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Amylyx Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Amylyx to invest in growth at high rates of return. When we think about Amylyx Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Fund Executives

Showing other executives

One Year Return

Patrick FowlerVericel Corp Ord
N/A
Yvonne MackieAgilent Technologies
N/A
Christopher DevallDominari Holdings
41
Eli Fry23Andme Holding Co
N/A
Franck MBAValneva SE ADR
57
Kristina MaximenkoDianthus Therapeutics
N/A
Michael MooreEquillium
N/A
Reza MBA23Andme Holding Co
N/A
Jacquie JD23Andme Holding Co
N/A
William Richards23Andme Holding Co
63
MS MDDiaMedica Therapeutics
51
Rashieda GluckDianthus Therapeutics
N/A
Hanneke SchuitemakerValneva SE ADR
N/A
Jaime MercadoDominari Holdings
N/A
Cindy DunkleDenali Therapeutics
N/A
Adam Auton23Andme Holding Co
N/A
Donald MBAVivani Medical
65
Christian TaucherValneva SE ADR
N/A
Tony EstradaDenali Therapeutics
N/A
Judson TaylorDianthus Therapeutics
N/A
Katie PengDenali Therapeutics
N/A
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis and other neurodegenerative diseases. Amylyx Pharmaceuticals is listed under Biotechnology in the United States and is traded on NASDAQ Exchange exchange. Amylyx Pharmaceuticals [AMLX] is traded in USA and was established 2018-03-26. Amylyx Pharmaceuticals is listed under Pharmaceuticals category by Fama And French industry classification.

Management Performance

Amylyx Pharmaceuticals Money Managers

Debra Canner, Global CHRO
Margaret MBA, Global Officer
Shauna Horvath, Head Marketing
Gina JD, Chief Counsel
Chris Aiello, Head GM
Justin Klee, CoCEO CoFounder
Camille MD, Chief Officer
James MBA, Chief Officer
MD MBA, Global Officer
Tammy Sarnelli, Global Affairs
Joshua Cohen, CoCEO CoFounder
Tom Holmes, Chief Officer
Gina Mazzariello, Chief Counsel
Keith White, Head Access
Lindsey Allen, Head Communications
Linda Arsenault, Chief Officer

Amylyx Etf Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right etf is not an easy task. Is Amylyx Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Amylyx Etf

Amylyx Pharmaceuticals financial ratios help investors to determine whether Amylyx Etf is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Amylyx with respect to the benefits of owning Amylyx Pharmaceuticals security.